BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31228553)

  • 1. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
    J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y
    Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
    J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
    Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
    Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
    Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.
    Wang C; Zhao K; Hu S; Huang Y; Ma L; Song Y; Li M
    BMC Cancer; 2020 Jun; 20(1):544. PubMed ID: 32522277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma.
    Minashi K; Nihei K; Mizusawa J; Takizawa K; Yano T; Ezoe Y; Tsuchida T; Ono H; Iizuka T; Hanaoka N; Oda I; Morita Y; Tajika M; Fujiwara J; Yamamoto Y; Katada C; Hori S; Doyama H; Oyama T; Nebiki H; Amagai K; Kubota Y; Nishimura K; Kobayashi N; Suzuki T; Hirasawa K; Takeuchi T; Fukuda H; Muto M
    Gastroenterology; 2019 Aug; 157(2):382-390.e3. PubMed ID: 31014996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
    Wang WT; Guo CQ; Cui GH; Zhao S
    World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
    Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
    Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
    Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
    Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy.
    Wen J; Yang H; Liu MZ; Luo KJ; Liu H; Hu Y; Zhang X; Lai RC; Lin T; Wang HY; Fu JH
    Ann Oncol; 2014 Sep; 25(9):1769-1774. PubMed ID: 24907633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.